A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Isomorphic Labs, backed by Google's parent company Alphabet, is preparing for its first human clinical trials for cancer drugs designed entirely by artificial intelligence.

Isomorphic Labs is a London-based drug developer that’s owned and operated by Alphabet Inc. The company was founded in 2021 ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

LONDON and BOSTON, June 17, 2025 /PRNewswire/ -- Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr.

Moreover, Alphabet, through Google Cloud and its own ventures like Isomorphic Labs, may view Recursion as the most advanced, real-world instantiation of AI-first drug discovery—built not on ...

See the latest Alphabet Inc Class A stock price (GOOGL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.